Movement disorder
Therapeutic area
Neurology
Rare disease
No
- Definition
- Neurological conditions resulting in abnormal voluntary or involuntary movement, which may impact the speed, fluency, quality and ease of movement.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Movement disorder
- Therapeutic area
- Neurology
- movement disorder
- movement disease
- movement disorder
- movement disorders
- All therapeutic areas
- Neurology
- Severity
- Unknown
- MONDO ID
- MONDO:0005395
- Parent condition
- MONDO:0005071
Related records
Broader conditions (4)
- Disease
- Disease by body system or component
- Human disease
- Nervous system disorder
Narrower conditions (403)
- Abetalipoproteinemia
- Aceruloplasminemia
- Acquired idiopathic torsion dystonia
- Acquired torsion dystonia
- Acute infantile liver failure-cerebellar ataxia-peripheral sensory motor neuropathy syndrome
- Adult-onset segmental dystonia
- Amyotrophic lateral sclerosis type 10
- Amyotrophic lateral sclerosis type 6
- Anismus
- Arthrogryposis
- Ataxia - deafness - intellectual disability syndrome
- Ataxia - oculomotor apraxia type 4
- Ataxia - telangiectasia variant
- Ataxia telangiectasia
- Ataxia with oculomotor apraxia type 3
- Ataxia-pancytopenia syndrome
- Ataxia-telangiectasia with generalized skin pigmentation and early death
- Atypical dopamine transporter deficiency syndrome
- Atypical pantothenate kinase-associated neurodegeneration
- Atypical progressive supranuclear palsy syndrome
Trials (375)
- [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
- 1-Octanol to Treat Essential Tremor
- A Biomarker Study of ATH434 in Participants With MSA
- A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor
- A Clinical Trial of PRAX-114 in Participants With Essential Tremor
- A Clinical Trial of PRAX-944 in Participants With Essential Tremor
- A Multicenter Pediatric Deep Brain Stimulation Registry
- A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease
- A New 3D Virtual Reality-based Upper Limb Training to Improve Dexterity in Parkinson's Disease
- A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease
- A Phase 2 RCT Study of CX-8998 for Essential Tremor
- A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
- A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling
- A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor
- A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
- A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
- A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)
- A Smartphone Application for Neurology and Telemedicine
- A Smartphone Based, Titrated Exercise Solution for Patients With Parkinson's Disease in Daily Life: Pilot Study
- A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
Approved drugs (5)
- Ioflupane I 123
- Penicillamine
- Trientine hydrochloride
- Valbenazine tosylate
- Zinc acetate
Drugs in development (15)
- Befiradol Phase 2
- Bevantolol hydrochloride Phase 1
- Carisbamate Phase 2
- Deutetrabenazine Phase 3
- Eliprodil Phase 2
- Famotidine Phase 2
- Levetiracetam Phase 3
- Piracetam Phase 3
- Propranolol hydrochloride Phase 2
- Pyridoxal phosphate Phase 2
- Pyridoxine Phase 3
- Sarizotan Phase 3
- Sarizotan hydrochloride Phase 2
- Tetrabenazine Phase 3
- Valbenazine Phase 3
Other linked drugs (1)
- Melatonin